| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6187791 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
|
US6399632 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Nov, 2012
(11 years ago) | |
| US5578610 | CHATTEM SANOFI | Piperidine derivatives |
Nov, 2013
(10 years ago) | |
| US7138524 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
| US7135571 | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
May, 2014
(9 years ago) | |
|
US5578610 (Pediatric) | CHATTEM SANOFI | Piperidine derivatives |
May, 2014
(9 years ago) | |
|
US7135571 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
|
US7138524 (Pediatric) | CHATTEM SANOFI | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
Nov, 2014
(9 years ago) | |
| US5738872 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US6113942 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5932247 | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Feb, 2015
(9 years ago) | |
| US5855912 | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Feb, 2015
(9 years ago) | |
|
US5855912 (Pediatric) | CHATTEM SANOFI | Pharmaceutical compositions for piperidinalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US6113942 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5738872 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
|
US5932247 (Pediatric) | CHATTEM SANOFI | Pharmaceutical composition for piperidinoalkanol compounds |
Aug, 2015
(8 years ago) | |
| US6037353 | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Mar, 2017
(7 years ago) | |
|
US6037353 (Pediatric) | CHATTEM SANOFI | Method of providing an antihistaminic effect in a hepatically impaired patient |
Sep, 2017
(6 years ago) | |
Allegra is owned by Chattem Sanofi.
Allegra contains Fexofenadine Hydrochloride.
Allegra has a total of 18 drug patents out of which 18 drug patents have expired.
Expired drug patents of Allegra are:
- US6187791*PED
- US6399632*PED
- US5578610
- US7138524
- US7135571
- US5578610*PED
- US7135571*PED
- US7138524*PED
- US5738872
- US6113942
- US5932247
- US5855912
- US5855912*PED
- US6113942*PED
- US5738872*PED
- US5932247*PED
- US6037353
- US6037353*PED
Allegra was authorised for market use on 25 July, 1996.
Allegra is available in suspension;oral, capsule;oral dosage forms.
Allegra can be used as method of using fexofenadine hcl in treating allergic rhinitis, relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years and for the relief of symptoms associated with uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years, use in treating allergic reactions, treatment of allergic rhinitis.
The generics of Allegra are possible to be released after 14 September, 2017.
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 1996
Treatment: Treatment of allergic rhinitis; Method of using fexofenadine hcl in treating allergic rhinitis; Relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years and for the reli...
Dosage: CAPSULE;ORAL; SUSPENSION;ORAL
ALLEGRA family patents
